Head to head
Veracyte vs Thermo Fisher Scientific
Side-by-side on the measures that matter, with a plain-English read. Full detail: VCYT · TMO
VCYT
Veracyte
43.16-3.34%
1-year price shape — +25% over the period
Quant Rating C · 61/100
vs
TMO
Thermo Fisher Scientific
662.06+0.83%
1-year price shape — +23% over the period
Quant Rating C · 64/100
1-year performance, rebased to 100
Veracyte edges it on the scoreable measures. Veracyte has done best over the past year (+25%); Veracyte trades cheapest on trailing earnings.
| VCYT | TMO | |
|---|---|---|
| Snapshot | ||
| Sector | Diagnostics & Research | Diagnostics & Research |
| Last price | 43.16 | 662.06 |
| Change today | -3.34% | +0.83% |
| 1-year return | +24.7% | +23.1% |
| Market cap | $3.47B | $244.79B |
| 52-week range | 29.46 – 60.91 | 434.50 – 694.33 |
| Valuation | ||
| P/E (TTM) | 30.83 | 35.63 |
| P/E percentile, own 5-yr range | 70th | 86th |
| P/B | 2.50 | 4.65 |
| Dividend yield | 0.00% | 0.27% |
| Profitability & growth | ||
| EPS (TTM) | 0.82 | 17.74 |
| Net profit (TTM) | $65.92M | $6.56B |
| Revenue (TTM) | $561.90M | $46.34B |
| Revenue growth (YoY) | +15.5% | +10.5% |
| Gross margin | 71.7% | 40.8% |
| Operating margin | 18.8% | 18.3% |
| Net margin | 20.4% | 15.0% |
| Free cash flow (TTM) | $165.99M | $7.32B |
| Ownership & sentiment | ||
| Institutional ownership | 111.2% | 93.1% |
| Insider activity (12mo) | 15 buy / 35 sell | 22 buy / 28 sell |
| Short interest (% of float) | 10.5% | 1.4% |
| Analyst consensus | 82% buy / 9% hold / 9% sell (11) | 88% buy / 12% hold (17) |
| Analyst price target | $60 (+39%) | $653 (-1%) |
| StockVane view | ||
| StockVane Quant Rating | C (61) | C (64) |
| Company | ||
| Employees | 755 | 125,000 |
| Founded | 2006 | 1956 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.